Overview:

The global cell and gene therapy manufacturing market demonstrates substantial growth potential over the forecast period. The market is projected to reach USD 32.24 billion in 2025, expanding to approximately USD 405.41 billion by 2035. This remarkable expansion is characterized by a compound annual growth rate (CAGR) of 28.7% between 2025 and 2035.

Several factors are driving this dynamic growth, including increasing investments in cell and gene therapy research and development, rising prevalence of chronic diseases, and technological advancements in manufacturing processes. The growing demand for personalized medicine and regenerative therapies further fuels market expansion.

The market is segmented by therapy type, scale, mode, workflow, and region. Cell therapies and gene therapies are the primary types, with manufacturing occurring at both clinical and commercial scales. Manufacturing can be conducted in-house or outsourced to contract manufacturing organizations (CMOs), involving various workflows such as upstream processing, downstream processing, and fill & finish.

North America, Europe, and Asia Pacific are the key regional markets. North America currently holds a significant market share, driven by the presence of numerous leading biotechnology and pharmaceutical firms, as well as advanced healthcare infrastructure.

Key players in the market, including Lonza Group, Thermo Fisher Scientific, Catalent Inc., WuXi Advanced Therapies and Fujifilm Diosynth Biotechnologies, are focused on expanding their manufacturing capabilities and developing innovative solutions to meet the growing demand.

The market’s future growth is contingent on overcoming manufacturing challenges, such as scalability and cost reduction, as well as addressing regulatory hurdles. Continuous innovation and strategic collaborations are essential for success in this rapidly evolving landscape.

Year On Year Growth Chart

“`html

“`

Key Companies Market Share